# Exenatide

Canonical source: https://retacompare.com/encyclopedia/exenatide

GLP-1 receptor agonist resistant to DPP-4 cleavage thanks to Gly substitution at position 2.

Reference facts

Also known asByetta, Bydureon, Exendin-4CategoryGLP-1 & MetabolicMechanism of actionGLP-1 receptor agonist resistant to DPP-4 cleavage thanks to Gly substitution at position 2.TargetsGLP-1RIndications under research or approvedType 2 DiabetesRegulatory status (reference entry)FDA-approved (Byetta 2005, Bydureon 2012)Half-life~2.4 hours (Byetta) / ~2 weeks (Bydureon LAR microsphere)SequenceHGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPSSequence notes39-residue peptide derived from exendin-4, originally isolated from the saliva of the Gila monster (Heloderma suspectum).Molecular weight (Da)4187PDB accession1JRJOriginator / sponsorAmylin / AstraZenecaFirst reported1992OriginDiscovered by John Eng in Gila monster venom; first peptide isolated from a non-mammalian source to become an FDA-approved drug.
    Primary References

Eng et al., JBC 1992 (Exendin-4 discovery)

EXSCEL CV outcomes, NEJM 2017


    Explore research articles about Exenatide


    This is an educational reference, not medical advice. Research findings do not establish safety or efficacy for self-administration. Consult the primary sources for study populations, limitations, and current regulatory status.

## Sources

- Eng et al., JBC 1992 (Exendin-4 discovery): https://pubmed.ncbi.nlm.nih.gov/1601846/
- EXSCEL CV outcomes, NEJM 2017: https://www.nejm.org/doi/full/10.1056/NEJMoa1612917